Source: Breathe 2006; 2: 266
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
J. Verbraecken. CPAP can decrease fatal and non-fatal cardiovascular events in OSAH. Breathe 2006; 2: 266

Member's Comments

No comment yet.

Related content which might interest you: Increased incidence of nonfatal cardiovascular events in stroke patients with sleep apnoea: effect of CPAP treatment Source: Eur Respir J 2012; 39: 906-912 Year: 2012 SAHS and stroke. CPAP compliance and new stroke events Source: Annual Congress 2011 - Obstructive sleep apnoea: the heart and the brain Year: 2011 Neutrophils and the increased risk of cardiovascular events in severe COPD Source: Annual Congress 2012 - Distinguishing phenotypes and dealing with comorbidities in primary care Year: 2012 Tiotropium and the risk of cardiovascular events and all-cause mortality Source: Annual Congress 2010 - Comorbidities and disease management in primary care Year: 2010 Respiratory polygraphy patterns and risk of cardiovascular events in patients with acute coronary syndrome Source: Virtual Congress 2021 – From phenotyping to different diagnostic tools for sleep breathing disorders Year: 2021 Can CPAP reduce adverse cardiovascular and metabolic effects of OSAS? Source: Research Seminar 2007 - Metabolic Aspects of the Obstructive Sleep Apnea Syndrome (OSAS) Year: 2007 Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial Source: Eur Respir J 2011; 37: 1128-1136 Year: 2011 The risk of hospitalization, near fatal and fatal asthma in relation to the perception of dyspnoea Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001 CPAP and measures of cardiovascular risks in patients with OSAS Source: Eur Respir J 2009; 33: 1520 Year: 2009 High rates of readmissions and life-threatening events in COPD survivors treated with non-invasive ventilation for acute respiratory railure Source: Eur Respir J 2003; 22: Suppl. 45, 401s Year: 2003 QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 OSAS and the incidence of cardiovascular disorders Source: Eur Respir J 2002; 20: Suppl. 38, 294s Year: 2002 Obstructive sleep apnoea doesn‘t increase risk of cardiovascular morbidity and mortality in patients with arterial hypertension Source: Annual Congress 2008 - Socioepidemiological studies in obstructive sleep apnoea Year: 2008 Co-morbidities and cardiovascular medications are the best predictors of mortality in patients with obesity-associated hypoventilation treated with long-term non-invasive ventilation Source: Annual Congress 2012 - Current trends in home mechanical ventilation Year: 2012 CPAP in the elderly with non-severe obstructive sleep apnea: effect on cardiovascular events and somnolence. Source: International Congress 2017 – Efficacy of and compliance with obstructive sleep apnoea treatment Year: 2017 Mortality in sleep apnoea syndrome: a review of the evidence Source: Eur Respir Rev 2007; 16: 203-210 Year: 2007 Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010 Beta-blocker-induced asthma Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009